Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

The Roundup – February 15, 2024

View this email in your browser February 15, 2024 Member News A new class of cancer drugs is coming: Pfizer & Arvinas‘ hot pursuit of protein degrader technology...

| By Kelley Gipson

The Roundup – February 8, 2024

View this email in your browser February 8, 2024 Member News Arvinas and Pfizer’s Vepdegestrant (ARV-471) receives FDA fast track designation for the treatment of patients with...

| By Kelley Gipson

Connecticut Rare Disease Forum

View this email in your browser We are thrilled to extend a special invitation to the upcoming Connecticut Rare Disease Forum, hosted by BioCT and The Jackson...

| By Kelley Gipson

The Roundup – February 1, 2024

View this email in your browser February 1, 2024 Member News Over 20 CT companies included in America’s Greatest Workplaces for Diversity 2024 (Boehringer Ingelheim, Pfizer)...

| By Kelley Gipson

The Roundup – January 25, 2024

View this email in your browser January 25, 2024 BioCT News “Think Big” to continue growth of CT’s life science industry Member News Arvinas appoints...

| By Kelley Gipson

The Roundup – January 4, 2024

View this email in your browser January 4, 2024 Member News Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases Enko featured...

| By Kelley Gipson

The Roundup – December 21, 2023

View this email in your browser December 21, 2023 Member News Alexion leaders talk research, booming biotech industry in New Haven BIO: SCOTUS should preserve FDA’s “mandated...

| By Kelley Gipson

Innovation is Under Threat

Innovation is Under ThreatLast Thursday, the Biden Administration released draft guidance outlining proposed factors that an agency may consider, including the “reasonableness of a product’s...